Pfizer

There is no patent yet on the experimental candidate PF-07321332, and ritonavir has been off-patent since last year

The collaboration aims to accelerate the adoption of renewable energy and reduce greenhouse gas emissions within the…

Pfizer expects to price its treatment, called Paxlovid, close to where rival Merck & Co Inc has priced its oral antiviral drug…

The company had, in July, forecast sales of $33.5 billion from the vaccine it sells with BioNTech

Pfizer made the proposal in a 52-page presentation to the US FDA, which included data from the recent Israeli study, which showed…

First subjects vaccinated in study of Pfizer’s RSV bivalent prefusion F subunit investigational vaccine candidate in adults aged…

While patients will be increasingly prescribed Viatris/Biocon’s Semglee over Sanofi’s Lantus due to its competitive pricing,…

Proposed acquisition strengthens Pfizer’s category leadership in oncology with addition of next-generation and investigational…

This once-daily treatment is an alternative to the currently-approved Xeljanz 5 mg twice-daily treatment of PsA

The US drug regulator has, in the past, reached out to companies whose drugs had N-nitrosodimethylamine (NDMA) over accepted…